person · Reporting owner
Fitzpatrick Alexander A
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Chief Legal Officer | June 12, 2026 | June 13, 2026 |
| Evofem Biosciences, Inc.EVFM · Entity 8607 | General Counsel and Secretary | February 18, 2022 | February 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 12, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,910 |
Reported balance
After 2026-06-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-12 · Sale · Disposed 3,355 · Balance 90,910 F1: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025.
Evofem Biosciences, Inc.
Report date February 18, 2022 · Filed February 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 516,422 |
Reported balance
After 2022-02-18 transaction · row 1
1 source rowRow 1 · 2022-02-18 · Grant · Acquired 300,000 · Balance 516,422 F1: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2032-02-18 | Direct | 300,000 |
Reported balance
After 2022-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-02-18 · Grant · Acquired 300,000 · Balance 300,000 F2: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022.
F2: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 13, 2026 00:04 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 3,355 | $10.00 | $33,550.00 |
DisclosureSEC source: 0001398595-26-000004 · form4-06132026_120640.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,910 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2 · balance_after: Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:25 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001398595-26-000002 · form4-01052026_090101.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001415889-25-014186 · form4-05222025_050505.xml · derivative · entry 3 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 100,000 shares Expires 2034-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 102,969 | $14.10 | $1,451,512.81 |
DisclosureSEC source: 0001415889-25-014186 · form4-05222025_050505.xml · nonDerivative · entry 2 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,613 F2 · price: The weighted average sale price for the transaction reported was $14.0966 and the range of prices were between $14.02 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 100,000 | $5.58 | $558,000.00 |
DisclosureSEC source: 0001415889-25-014186 · form4-05222025_050505.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,582 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 152,300 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001415889-25-000463 · form4-01032025_040130.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,300 Underlying: Common Stock · 152,300 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:38 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001209191-24-000804 · doc4.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| September 29, 2023 Filed Oct 2, 2023 20:23 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | PurchaseCommon Stock | 46,258 | $3.78 | $174,994.01 |
DisclosureSEC source: 0001209191-23-051073 · doc4.xml · nonDerivative · entry 2 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,227 F3 · price: The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.70 to $3.85, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 20:23 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | PurchaseCommon Stock | 40,000 | $3.62 | $144,960.00 |
DisclosureSEC source: 0001209191-23-051073 · doc4.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,969 F1 · price: The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.60 to $3.64, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · balance_after: Includes 2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2023. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 700,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-23-001931 · doc4.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on December 1, 2023, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:08 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $0.49 | $0.00 |
DisclosureSEC source: 0001618835-22-000031 · wf-form4_164565046081887.xml · derivative · entry 2 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-02-18 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 18, 2022. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 16:08 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-22-000031 · wf-form4_164565046081887.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,422 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2022. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:06 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Disposition to issuerCommon Stock | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-22-000006 · wf-form4_164133035440575.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,422 F1 · security: The disposition is due to forfeiture under the vesting provisions of restricted stock awards granted on 2/3/2021. Read SEC document |
| December 20, 2021 Filed Dec 20, 2021 16:20 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 25,000 | $0.39 | $9,725.00 |
DisclosureSEC source: 0001618835-21-000273 · wf-form4_164003523317319.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,422 Read SEC document |
| June 10, 2021 Filed Jun 10, 2021 19:29 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 10,000 | $1.03 | $10,250.00 |
DisclosureSEC source: 0001618835-21-000146 · wf-form4_162336776279756.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,422 Read SEC document |
| May 20, 2021 Filed May 21, 2021 16:26 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 42,120 | $0.86 | $36,223.20 |
DisclosureSEC source: 0001618835-21-000137 · wf-form4_162162880189777.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,422 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 20, 2021. No shares were sold in connection with this transaction. Read SEC document |
| February 03, 2021 Filed Feb 3, 2021 19:57 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001618835-21-000009 · wf-form4_161240022820711.xml · derivative · entry 2 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-02-03 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of forty-eight (48) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 3, 2021 19:57 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-21-000009 · wf-form4_161240022820711.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,542 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2021. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 17:14 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 9,090 | $2.20 | $19,998.00 |
DisclosureSEC source: 0001618835-20-000246 · wf-form4_160573767675790.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,542 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 17:41 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 31,590 | $3.31 | $104,562.90 |
DisclosureSEC source: 0001618835-20-000185 · wf-form4_159165249625617.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,452 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 5, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 22, 2020 Filed May 26, 2020 17:16 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 39,487 | $4.99 | $197,040.13 |
DisclosureSEC source: 0001618835-20-000158 · wf-form4_159052779414010.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,042 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 22, 2020. No shares were sold in connection with this transaction. Read SEC document |
| May 06, 2020 Filed May 8, 2020 12:30 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 7,802 | $5.24 | $40,882.48 |
DisclosureSEC source: 0001618835-20-000111 · wf-form4_158895543229158.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,529 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on May 6, 2020. No shares were sold in connection with this transaction. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:33 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $4.87 | $0.00 |
DisclosureSEC source: 0001618835-20-000021 · wf-form4_158111117130256.xml · derivative · entry 2 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-02-05 F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from February 5, 2020. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 16:33 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-20-000021 · wf-form4_158111117130256.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,331 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2020. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 17:15 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 7,747 | $6.22 | $48,186.34 |
DisclosureSEC source: 0001618835-19-000203 · wf-form4_157480648797283.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,331 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on November 25, 2019. No shares were sold in connection with this transaction. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 20:17 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 7,747 | $5.74 | $44,467.78 |
DisclosureSEC source: 0001618835-19-000182 · wf-form4_157438545260854.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,078 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on November 20, 2019. No shares were sold in connection with this transaction. Read SEC document |
| October 16, 2019 Filed Oct 17, 2019 14:15 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 18,427 | $5.01 | $92,319.27 |
DisclosureSEC source: 0001628280-19-012348 · wf-form4_157133610914438.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,825 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on October 16, 2019. No shares were sold in connection with this transaction. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 18:36 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 1,296 | $5.13 | $6,648.48 |
DisclosureSEC source: 0001618835-19-000154 · wf-form4_156685897030733.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,252 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on August 22, 2019. No shares were sold in connection with this transaction. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 16:38 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 7,777 | $6.36 | $49,461.72 |
DisclosureSEC source: 0001618835-19-000123 · wf-form4_156037189920094.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,548 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on June 10, 2019. No shares were sold in connection with this transaction. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:42 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 1,298 | $3.55 | $4,607.90 |
DisclosureSEC source: 0001618835-19-000049 · wf-form4_155433132454011.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,325 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on April 1, 2019. No shares were sold in connection with this transaction. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 16:10 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-19-000019 · wf-form4_155130182924120.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,623 F1 · shares: The restricted stock awards will vest based on the Issuer's achievement of certain performance milestones in 2019. Read SEC document |
| November 28, 2018 Filed Nov 29, 2018 18:10 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001618835-18-000117 · wf-form4_154353301888940.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 0 shares Expires 2028-11-28 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 28, 2018. Read SEC document |
| November 28, 2018 Filed Dec 3, 2018 12:51 UTC Amendment | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001618835-18-000129 · wf-form4a_154385946011509.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-11-28 F1 · shares: The original Form 4, filed on November 29, 2018, is being amended to update the number of shares reported in Column 5(A) and Column 7 of Table II. F2 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from November 28, 2018. F1 · derivative.underlying_shares: The original Form 4, filed on November 29, 2018, is being amended to update the number of shares reported in Column 5(A) and Column 7 of Table II. Read SEC document |
| October 16, 2018 Filed Oct 17, 2018 12:43 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | Tax withholdingCommon Stock | 17,377 | $3.78 | $65,685.06 |
DisclosureSEC source: 0001618835-18-000092 · wf-form4_153979460163169.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,623 F1 · shares: Shares withheld by the Issuer to satisfy statutory tax withholding requirements upon vesting of restricted stock awards occurring on October 16, 2018. No shares were sold in connection with this transaction. Read SEC document |
| August 21, 2018 Filed Aug 21, 2018 16:06 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 500 | $2.27 | $1,135.00 |
DisclosureSEC source: 0001618835-18-000090 · wf-form4_153488195492075.xml · nonDerivative · entry 2 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 16:06 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | PurchaseCommon Stock | 4,500 | $2.20 | $9,900.00 |
DisclosureSEC source: 0001618835-18-000090 · wf-form4_153488195492075.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,500 Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 16:23 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 0 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001618835-18-000077 · wf-form4_153324137208204.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,500 Underlying: Common Stock · 104,500 shares Expires 2028-07-31 F1 · derivative.exercise_date: The shares of common stock exercisable pursuant to the option will vest in a series of thirty-six (36) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from July 31, 2018. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:57 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001618835-18-000047 · wf-form4_153065141230310.xml · nonDerivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · shares: The restricted stock awards vest in two equal installments on each of October 16, 2018 and 2019 subject to Mr. Fitzpatrick's continued employment. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 17:19 UTC | Evofem Biosciences, Inc. EVFM · Entity 8607 | GrantStock option (right to buy) · Derivative | 275,000 | $0.00 Strike: $7.29 | $0.00 |
DisclosureSEC source: 0001209191-18-019640 · doc4.xml · derivative · entry 1 Fitzpatrick Alexander A · CIK 0001398595 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: Mr. Fitzpatrick acquired a vested interest in 25% of the shares of common stock exercisable pursuant to the option effective as of March 12, 2018 (the "Vesting Start Date"). The remaining shares shall vest in a series of twenty-four (24) successive equal monthly installments upon completion of each additional month of service for the Issuer measured from the Vesting Start Date. The option was awarded in connection with Mr. Fitzpatrick's service as Secretary and General Counsel. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.